1367360-07-3

Basic information

• Product Name: 3-(4-pyridylmethyl)-3'-O-cholesteroxyacetyl-5-O-(4,4'-dimethoxytriphenylmethyl)thymidine
• CAS NO: 1367360-07-3
• Molecular Weight: 1062.4
• Mol File: 1367360-07-3.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-pyridylmethyl)-3'-O-cholesteroxyacetyl-5-O-(4,4'-dimethoxytriphenylmethyl)thymidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-pyridylmethyl)-3'-O-cholesteroxyacetyl-5-O-(4,4'-dimethoxytriphenylmethyl)thymidine(1367360-07-3)
• EPA Substance Registry System: 3-(4-pyridylmethyl)-3'-O-cholesteroxyacetyl-5-O-(4,4'-dimethoxytriphenylmethyl)thymidine(1367360-07-3)

Safety Data

• Hazardous Substances Data: 1367360-07-3(Hazardous Substances Data)

Upstream product

• 40615-39-2 5'-O-(4-4'-dimethoxytrityl)thymidine 
• 73870-24-3 4-bromomethyl pyridine hydrobromide 
• 57-88-5 cholesterol 
• 1361208-77-6 3-(4-pyridylmethyl)-5’-O-(4,4′-dimethoxytriphenylmethyl)-thymidine 
• 30656-77-0 cholest-5-en-3β-yloxyacetic acid 

Relevant articles and documents

Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy

A novel ruthenium complex, linked to a cholesterol-containing nucleolipid (named ToThyCholRu), stabilized by lipid aggregates for antineoplastic therapy is presented. In order to retard the degradation kinetics typically observed for several ruthenium-based antineoplastic agents, ToThyCholRu is incorporated into a liposome bilayer formed by POPC. The resulting nanoaggregates contain up to 15% in moles of the ruthenium complex, and are shown to be stable for several weeks. The liposomes host the ruthenium - nucleolipid complex with the metal ion surrounded by POPC lipid headgroups and the steroid moiety inserted in the more external acyl chain region. These rutheniumcontaining liposomes are more effective in inhibiting the growth of cancer cells than a model NAMI-A-like ruthenium complex, prepared for a direct evaluation of their antiproliferative activity. These results introduce new perspectives in the design of innovative transition-metal-based supramolecular systems for anticancer drug vectorization. (Graph Presented)